Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Investment analysts at Zacks Research issued their FY2027 EPS estimates for shares of Intellia Therapeutics in a report released on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the company will post earnings per share of ($4.87) for the year. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share.
Several other research analysts have also recently weighed in on NTLA. Truist Financial dropped their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Wedbush reissued a "neutral" rating and set a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Oppenheimer reduced their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating on the stock in a research note on Monday, January 13th. Finally, HC Wainwright began coverage on shares of Intellia Therapeutics in a research note on Wednesday, March 5th. They set a "buy" rating and a $30.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Intellia Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $37.56.
Get Our Latest Report on NTLA
Intellia Therapeutics Price Performance
Shares of NTLA stock traded up $0.09 during trading hours on Monday, reaching $8.40. 2,720,401 shares of the company were exchanged, compared to its average volume of 3,267,146. Intellia Therapeutics has a fifty-two week low of $8.11 and a fifty-two week high of $28.23. The stock's fifty day moving average is $10.03 and its two-hundred day moving average is $13.93. The company has a market cap of $869.54 million, a price-to-earnings ratio of -1.54 and a beta of 1.97.
Insider Transactions at Intellia Therapeutics
In related news, CEO John M. Leonard sold 26,807 shares of the business's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 29,000 shares of company stock valued at $352,551 over the last quarter. Corporate insiders own 3.20% of the company's stock.
Institutional Trading of Intellia Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. Quest Partners LLC increased its position in shares of Intellia Therapeutics by 181.6% in the third quarter. Quest Partners LLC now owns 19,748 shares of the company's stock valued at $406,000 after acquiring an additional 12,734 shares during the last quarter. Jennison Associates LLC grew its position in shares of Intellia Therapeutics by 21.6% in the third quarter. Jennison Associates LLC now owns 47,899 shares of the company's stock valued at $984,000 after purchasing an additional 8,497 shares during the last quarter. Intech Investment Management LLC bought a new position in Intellia Therapeutics during the third quarter worth about $580,000. Charles Schwab Investment Management Inc. increased its stake in Intellia Therapeutics by 4.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company's stock worth $17,006,000 after acquiring an additional 37,714 shares during the period. Finally, D.A. Davidson & CO. raised its holdings in Intellia Therapeutics by 34.3% in the 3rd quarter. D.A. Davidson & CO. now owns 16,250 shares of the company's stock valued at $334,000 after acquiring an additional 4,150 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
See Also
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
